Humana Shares Plunge Following Earnings Forecast Slash

US health insurer Humana witnessed a dramatic sell-off in its stock after presenting mixed quarterly results and significantly revising its full-year earnings guidance downward. Although adjusted earnings surpassed market expectations, investors reacted sharply to the reduced GAAP profit outlook, driving the share price down more than 12% within days.

Legal Setback Compounds Financial Pressure

A significant factor behind the negative investor sentiment stems from a legal ruling on October 14, 2025. Humana lost a court dispute concerning its Medicare Advantage Star Ratings for 2025. This legal defeat is projected to have substantial financial repercussions in 2026, including:

• A reduction in the proportion of Medicare members enrolled in highly-rated plans, falling to 20% from a previous 25%.
• An estimated $3 billion in Medicare bonus payments is now at risk.
• The company anticipates a “significant decline” in its higher-rated Medicare plans.

Strong Revenue Obscured by Profit Weakness

For the third quarter of 2025, Humana reported robust performance in certain areas. Its adjusted earnings per share came in at $3.24, notably exceeding analyst forecasts of $2.95. Furthermore, quarterly revenues climbed 11.4% to $32.65 billion.

However, these positive figures were overshadowed by a steep decline in GAAP earnings, which collapsed to $1.62 per share from $3.98 in the same period a year earlier. The primary shock to the market was the company’s decision to lower its full-year 2025 GAAP earnings forecast from $13.77 to $12.26 per share. Management attributed this revision to escalating medical costs and necessary strategic investments aimed at maintaining long-term competitiveness.

Should investors sell immediately? Or is it worth buying Humana?

A Glimmer of Hope Amidst the Gloom

Despite the challenging outlook, one operational metric showed improvement. Humana updated its forecast for Medicare Advantage membership attrition, now expecting to lose 425,000 members, an improvement over the initial projection of 500,000. The company credited this to enhanced customer retention efforts and stronger sales execution.

Divergent Views from Wall Street

Equity researchers have issued mixed responses to the news. Goldman Sachs initiated coverage with a sell recommendation and a price target of $235. In contrast, analysts at Bank of America and Mizuho displayed more optimism, raising their respective price targets for the insurer. The consensus average price target currently sits in a range between $291 and $299, which remains substantially above the stock’s present trading level.

From a technical analysis perspective, Humana’s shares are exhibiting clear weakness. The current price trades well below its 50-day moving average of $278, and the stock has declined over 12% in the past twelve months. The critical question for investors is whether Humana can orchestrate a recovery or if the downward trend is set to continue.